Get the latest scientific news and resources on diseases of the bones, joints, muscles, and skin from the NIAMS. The NIAMS funds the following types of grants: Research Grants The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA. Open Mike: Introducing the Stephen I. Katz Early Stage Investigator Research Grant Program. Candidates must have completed their specialty and, if applicable, subspecialty training prior to receiving an award.Duration: 3 to 5 yearsProvisions: Support is provided for salary up to $100,000 for a minimum 75% effort (with the exception of orthopaedic surgeons, who may devote a minimum of 50% effort*), fringe benefits, and other research expenses up to $30,000.Applications Due: Standard dates*Please see NOT-AR-16-012, Midcareer Investigator Award in Patient-Oriented Research, To support protected time for clinicians to allow them time for patient-oriented research and to act as mentors for beginning clinical investigators. A temporary change may be allowed with NIGMS' prior approval under circumstances such as sabbatical leave, medical conditions, disability, or personal or family situations. For support to develop and/or implement a program as it relates to a category in one or more of the areas of education, information, training, technical assistance, coordination, or evaluation. See the NIH Grants Policy Statement for additional information on this reporting requirement. Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional) National To support research projects that will enhance the capability of resources to serve biomedical research. A detailed experimental plan should not be provided. NIAMS will support the most meritorious request, based upon availability of funds. When multiple years are involved, recipients will be required to submit theResearch Performance Progress Report (RPPR)annually and financial statements as required in theNIH Grants Policy Statement. A letter from the subcontract PD/PI should be included making it clear why they cannot participate in collaborative research with the PD/PI without support from the MIRA. Consistent with the NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the NIH Grants Policy Statement. Larger award amount than the current average NIGMS R01 award to ESIs. Activities could include the establishment of the research team and finalizing collaborations; the development of tools for data management and oversight of the trial; the development or refinement of the trial design; the development of other essential elements of the study, such as the protocol, manual of operations, informed consent forms, recruitment strategies; and to collect feasibility data to estimate recruitment potential. If there are further questions, applicants should consult with the NIGMS Scientific/Research staff (listed in Section VII. Supplement request should be submitted electronically. NIAMS only accepts new/resubmission applications from Associate Professors. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301. Appendix: Only limited Appendix materials are allowed. Is there evidence that the research program will evolve appropriately as the work is performed? Awardees will provide updates at least annually on implementation of the PEDP. Funds are expected to be awarded by July 1st and Jan 1st, respectively. An Early Stage Investigator (ESI) is a new investigator who has completed his or her terminal research degree or medical residencywhichever date is laterwithin the past 10 years and has not yet competed successfully for a substantial, competing NIH research grant. NINDS uses an extended R01 payline to make it easier for early-stage investigators to get an award, or put another way, to normalize the success rate of early-stage investigators so they have the same chance of success as established investigators. CSRs primary role is to handle the receipt and review of ~ 75% of the grant applications that NIH receives. Telephone: 301-402-7469 or 866-504-9552 (Toll Free), General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources) For this NOFO, do not suggest a Scientific Review Group because applications will be reviewed by MIRA-specific study sections or special emphasis panels. http://grants.nih.gov/grants/new_investigators/index.htm). NCI FY2017: R21 Applications, Awards and Success Rates Figure 5: All Investigators: Experienced, New and Early Stage Figure 6: Experienced Investigators The Maximizing Investigators' Research Award (MIRA) under this Notice of Funding Opportunity (NOFO) provides support for a program of research in an early stage investigator's laboratory that falls within the mission of NIGMS. Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. U.S. Department of Health and Human Services, U01: Research Project Cooperative Agreement, U34: Implementation Planning Cooperative Agreement, NIH Policy for Review and Resubmission of New Investigator R01 Applications, NIH New and Early Stage Investigator Policies. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. Only single PD/PI applications are allowed. For more information, see https://grants.nih.gov/policy/clinical-trials/reporting/index.htm. Applications due: Standard datesAdditional Information: Active R03 funding opportunity: PAR-22-119 Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award. A PD/PI may submit an R01 application and a MIRA application within the same council round. Optional: Accepting applications that either propose or do not propose clinical trial(s). Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). In Section A: Senior/Key Person, provide an entry for the PD/PI, including the appropriate level of effort, and enter $0 for Requested Salary and $0 for Fringe Benefits. In Section H: Indirect Costs, enter your institutional "indirect cost type," "indirect cost rate," "indirect cost base" and "funds requested.". See NOT-AR-10-023 for additional information regarding NIAMS support for innovative research using R21 grants. Women, individuals from underrepresented racial and ethnic groups, from disadvantaged backgrounds, or with disabilities (NOT-OD-22-019) are always encouraged to apply for NIH support. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. In lieu of preliminary data from the PD/PI's independent lab, feasibility of the program may be demonstrated through literature citation, data from other sources, or data generated by the applicant as a graduate student or postdoctoral fellow. Do not present or include figures or preliminary data. WebSuccess Rates of R01 Applications from Early Stage Investigators. NIAMS has 2 receipt dates for this program: May 1st and Nov 1st. We are particularly interested in applications from physician-scientists. Subscriptions Applications that are incomplete or non-compliant, or that do not fall within the NIGMS mission, will not be reviewed. NIH Will Consider Your Career Stage If You submit an R01 grant application You are an Early Stage Investigator (ESI) A New Investigator is someone who has not A program to invite eligible institutions to submit a pre-application (also known as a white paper or prcis) to facilitate certain approaches or economies, such as reducing burden on the applicant community, for a funding opportunity. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement. The following items are to be included in the PHS 398 Career Development Award Supplemental Form: 1. Has the investigator included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed research program? Pre-award costs are allowable only as described in the NIH Grants Policy Statement. If a special payline award is made to an eligible investigator any other eligible applications from that investigator To what extent do the efforts described in the Plan for Enhancing Diverse Perspectives further the significance of the project? Fellowships to provide opportunities for experienced scientists to make major changes in the direction of research careers, to broaden scientific background, and to acquire new research capabilities regarding arthritis, muscle, bone, musculoskeletal, and/or skin diseases. 22. See your administrative office for instructions if you plan to use an institutional system-to-system solution. *** For the BTOD grants, the PD/PI must maintain 51% research effort toward their MIRA, and 3 person months' effort toward the BTOD. As applicable for the proposed research program, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score. Supplements to MIRAs: MIRAs will be eligible for Research Supplements to Promote Diversity in Health-Related Research , for Research Supplement to Promote Re-Entry into Biomedical and Behavioral Research Careers , and for Administrative Supplements for Equipment Purchases . National Institute of Environmental Health Sciences Office of the Director, NIH Notice of NHGRI Participation in PAR-22-181, "Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (NOT-HG-23-040) National Human Genome Research Institute Equipment quote(s) may be included here. 2. For step-by-step instructions, see the ESI Extension Request online help or watch the video tutorial ESI Status Extension Request on the eRA Videos page. NIH separates the review process from funding decisions. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. Do not complete a separate R&R Budget form for the Budget Type Subaward/Consortium or the R&R Subaward Budget Attachment form. Refer to NIH's Early Stage Investigator policies for information about what awards impact ESI status. You must use one of these submission The MIRA will replace all current NIGMS research funding of the laboratory of the PD/ PI with the exception of those listed in Section I under Overlap during peer review. Enhance investigators' ability to move into research areas that are distinct from those of their postdoctoral mentors by not requiring or expecting preliminary data, which could lead to new scientific discoveries. If your status isn't correct, contact the, Once you apply for and receive certain NIH awards, you no longer qualify as anESI. For the purpose of this NOFO, a program of research is a collection of projects in the investigator's lab that are relevant to the mission of NIGMS. Clinical research that involves recruitment of human subjects at more than one site, or the substantial financial support of multiple collaborators and subcontractors, is not allowed, because these fixed commitments are not consistent with the highly flexible nature of the MIRA program. All instructions in the SF424 (R&R) Application Guide must be followed. Clinical trials that are designed to test safety and efficacy of interventions (Phase I, Phase II, Phase III) for the purpose of future clinical treatment and/or regulatory approval are not permitted in MIRA. ESIs are new investigators who are within 10 years of completing either their terminal research degree or their medical residency (whichever is later) at the time they apply for R01 grants. Recently issued trans-NIH policy notices may affect your application submission. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described. EarlySteps Provider Specialist. The original specific aims of the research project and a brief progress report including the roles of personnel working on the project. Pregnancy and childbirth appear to be a significant contributor to the underemployment of women scientists and engineers, given that pregnancy can impact research productivity. National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892U.S. There are many benefits that flow from a broad scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the research, advancing the likelihood that underserved populations participate in, and benefit from research, and enhancing public trust. The recipient must also make semiannual disclosures regarding such proceedings. New and Early Stage Investigators A Program Director or Principal Investigator (PD/PI) is considered a New Investigator (NI) if he/she has not previously competed successfully as PD/PI for a significant NIH independent research award. In this case, the Clinical Research Education and Career Development (CRECD) grant awards support development and implementation of curriculum-dependent programs in minority institutions to train selected doctoral and postdoctoral candidates in clinical research leading to a Master of Science in Clinical Research or Master of Public Health in a clinically relevant area. We are interested in applications that meet the eligibility requirements for either the Clinical Research Program or the Pediatric Research Program. Read about our outreach programs and publications. There are three parent announcements for the R01 activity code. Innovation and the potential for commercialization are two important aspects of the review criteria considered in the scientific and technical merit evaluation process. Investigators with K awards from NIGMS will be required to relinquish the K award prior to the start date of the MIRA. Generally, summary statements will be available no later than 30 days before Council. The goal of this MIRA program is to provide support for an ESIs research program that is within the NIGMS mission, to offer an opportunity for these ESIs to receive support as early as possible in their careers, to give them relative freedom in pursuing their research goals, and to encourage them to move into research areas that are distinct from those of their postdoctoral mentors. Definition and other information provided under the R15 Guidelines related links. Twitter Increase flexibility for investigators to adapt to important new research directions as opportunities arise, rather than being bound to specific aims proposed in advance of the studies. Has the PD/PI shown evidence of being creative and adaptable, able to recognize new opportunities and to explore new areas of scientific inquiry, and openness to the use of new systems and strategies, as appropriate for the proposed research program? No. These centers will provide new opportunities for interdisciplinary approaches to advancing studies on how sex and gender factors affect women's health. Is experiencing a serious personal health issue or illness and/or debilitating condition. In addition, for applications involving clinical trials: Are the scientific rationale and need for a clinical trial to test the proposed hypothesis or intervention well supported by preliminary data, clinical and/or preclinical studies, or information in the literature or knowledge of biological mechanisms? Preference in funding decisions for R21 grants will be given to projects within the NIAMS mission areas that are especially innovative, ground-breaking and have a high potential impact on these fields. Applications should include a letter signed by the Institutional Business Official certifying PI's eligibility for the supplement award. Applicants must complete all required registrations before the application due date. NIAMS also has funding opportunities for R21 grants on specific topics. Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s). Funds are expected to be awarded by July 1st and Jan 1st, respectively. Before proceeding with any supplement request, PIs are advised to contact their program officer to discuss scientific need and their grants management specialist to discuss budget and policy issues. or Ph.D. or equivalent.Duration: Up to 3 yearsCommitment: Full-time research fellowshipProvisions:NRSA Stipends, Tuition/Fees, and Institutional AllowanceApplications Due: Standard dates. Is the scientific rationale/premise of the study based on previously well-designed preclinical and/or clinical research? Will creative strategies be employed as needed and appropriate to address the research questions posed? Are the plans to add or drop enrollment centers, as needed, appropriate? The NIGMS MIRA differs from other institutes' R35 awards in that MIRA is not a grant designed to support a small number of investigators; instead, the Institute intends to have at least 60% of the R01-equivalent pool eventually be MIRAs as stated in the Institute's strategic plan. Similarly, early career stage applicants may not have yet published independently as senior or corresponding authors, and the absence of these publications should not be viewed as a weakness. Applications that are determined to be outside of the NIGMS mission will not be accepted for review. Should the applicant organization successfully compete for an award, recipients of federal financial assistance (FFA) from HHS will be required to complete an HHS Assurance of Compliance form (HHS 690) in which the recipient agrees, as a term and condition of receiving the grant, to administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, age, sex and disability, and agreeing to comply with federal conscience laws, where applicable. See Section III of this NOFO for information on registration requirements. Only one award per eligible investigator may be considered for this special payline. Supplements may not be awarded on a grant that is a No Cost Extension (NCE). Reviewers will comment on whether the Resource Sharing Plan(s) (e.g., Sharing Model Organisms) or the rationale for not sharing the resources, is reasonable. Indicators of scientific accomplishments / productivity, such as: Peer-reviewed research publications and citations. Do they have appropriate expertise in study coordination, data management and statistics? Following initial peer review, recommended applications will receive a second level of review by the National Advisory General Medical Sciences Council. For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources. Is the prior research that serves as the key support for the proposed research rigorous? YouTube. I am thrilled to announce that I have been awarded a new @NIDDKgov /@NIH Stephen I. Katz Early-Stage Investigator Research Project Grant-R01 providing $2.3 million in funding over five years to advance our research efforts A NIAMS grant may only support one Re-Entry Supplement candidate at any given time. The STTR program is a set-aside program designed to support innovative research that has the potential for commercialization of the subject research conducted cooperatively by a small business concern and a research institution. First Competitive Renewal of R01 Applications From Former NIDDK ESIs NIDDK seeks to encourage the stable integration of early career researchers into the scientific research workforce. Peer reviewers look more at your potential than achievementthey weigh your academic and research background heavily. Is the overall strategy well-reasoned and appropriate to accomplish the overall goals of the research program? A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. For the purpose of the STAR Program, NIAMS defines these investigators as those who have successfully renewed a first NIAMS-supported R01 which was received no earlier than 2009 with Early Stage Investigator (ESI) status. Are the relevant concepts and methods sufficiently established by the prior literature, previous work or preliminary data? Project-based opportunities to enhance the research environment to benefit early- and mid-career investigators. For Established Investigator or New Investigator MIRA applications, it is NOT okay to have similar ReWARD application under review at the same time. It qualifies only if all the PIs are ESI. The PEDP should provide a holistic and integrated view of how enhancing diverse perspectives is viewed and supported throughout the application and can incorporate elements with relevance to any review criteria (significance, investigator(s), innovation, approach, and environment) as appropriate. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day. For each budget period: 1. Applications received outside of these dates will be returned, but could be resubmitted during the during the next receipt period if appropriate. Use the NIH ASSIST system to prepare, submit and track your application online. is acting as the primary caregiver within the first year of the birth or adoption of a child. For this NOFO, the instructions are hereby modified as follows: a) Under Section B.1 What are the major goals of the research? Letter from the Director: New NIH Research Grants Honor Legacy of Former NIAMS Director Stephen I. Katz, M.D., Ph.D. Katz Early Stage Investigator R01Frequently Asked Questions (FAQs). Department of Health and Human Services partners. Am I still eligible if I'm an Early Stage Investigator but have an R01 application pending? Notes: The status of R01 and DP2 awardees is determined for the assigned fiscal year of the award. These provide support for an investigator to collect key preliminary data in order to submit an improved revised R01 application, but you should understand that NIDDK has only enough funds to make very few of these awards. NIH sets target numbers for funding early-stage R01 investigators. Other Plan(s): Note: Effective for due dates on or after January 25, 2023, the Data Management and Sharing Plan will be attached in the Other Plan(s) attachment in FORMS-H application forms packages. Phase 1 Exploratory/Developmental Cooperative Agreement. The ORWH promotes, stimulates, and supports efforts to improve the health of women through biomedical and behavioral research. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application (see Section IV.2 SF424(R&R) Other Project Information. Does the NIH Directors New Innovator Award remove your Early Stage Investigator status? Renewals: ESI MIRA recipients will be eligible to renew their MIRAs through MIRA NOFOs not limited to ESIs, e.g., through PAR-22-180 and reissuances of it. Only those application types listed here are allowed for this NOFO. New Investigators are funded according to the funding institutes programmatic interests. At least 40% of the research project is to be conducted by the small business concern, and at least 30% of the work is to be conducted by the single, partnering research institution. will give birth within the next 3 months or has given birth in the past 12 months. Does the application adequately address the capability and ability to conduct the trial at the proposed site(s) or centers? NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO. NIHTurning Discovery Into Health NIAMS strongly encourages electronic submission of the completed application request, including all appropriate signatures and supporting documents, via eRA Commons or Grants.gov. Please visit our Find Your NINDS Program Director page to learn more about contacting Program Directors, Grants Management Specialists, Scientific Review Officers, and Health Program Specialists. For Early Stage Investigator MIRA applications it is okay to have a similar ReWARD application under review at the same time, but only one application will be funded. Helping investigators transition to NIAMS has 2 receipt dates for this program: May 1st and Nov 1st. Transfer of a MIRA to a foreign institution will not be allowed. The MIRA PD/PI will be required to relinquish their involvement in the multi-component grant at the end of its competitive segment. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO. 11/18/2019 12:56 PM, Biophysics, Biomedical Technology, and Computational Biosciences, Genetics and Molecular, Cellular, and Developmental Biology, Pharmacology, Physiology, and Biological Chemistry, Training, Workforce Development, and Diversity, FAQs About Noncompliance and Withdrawal of Applications, Native American Research Centers for Health (NARCH), Science Education Partnership Awards (SEPA), Parent Announcements for Investigator-Initiated Applications, Research With Activities Related to Diversity (ReWARD), Maximizing Investigators' Research Awards (MIRA), Multidisciplinary Teams/Collaborative Research, Grant Application and Post-Award Information, Talking to NIH Staff About Your Application and Grant, Research Using Human Subjects or Specimens, Chemistry, Biochemistry, and Pharmacology, Webinars for the NIGMS Training Community, Grant Writing Webinar Series for Institutions Building Research and Research Training Capacity, Budget, Financial Management, and Congressional Material, Data Integration, Modeling, and Analytics, http://grants.nih.gov/grants/new_investigators/index.htm, U.S. Department of Health and Human Once the multiple PI application is funded, you lose your ESIstatus. Under these policies, an applicant's status as a new investigator is one of the criteria used in funding decisions made by the Institute. Anticipated Announcement and Award Dates. See FOA for guidelines: https://grants.nih.gov/grants/guide/pa-files/PA-20-272.html Applications with multiple PDs/PIs will not be accepted. Trans-disciplinary research projects and collaborations among investigators from different fields. eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threatensubmission by the due date, and post-submission issues), Finding Help Online:https://www.era.nih.gov/need-help(preferred method of contact) Additionally, NIGMS will not accept assignment of an NIH Directors Transformative Research Award (TRA) R01 or NIH Directors Pioneer Award (DP1) application if the PD/PI has a MIRA. All instructions in the SF424 (R&R) Application Guide must be followed except as detailed below. The ORWH announces the Specialized Centers of Interdisciplinary Research on Sex and Gender Factors Affecting Women's Health (SCOR) program. The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education: Nonprofits Other Than Institutions of Higher Education. Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional) National Institutes of Health (NIH) 01 May 2023 $350,000USD Notice of Special Interest: Administrative Supplements to NIH-funded T32 and TL1 Training Grants to Better Integrate I am thrilled to announce that I have been awarded a new @NIDDKgov /@NIH Stephen I. Katz Early-Stage Investigator Research Project Grant-R01 providing $2.3 If a Changed/Corrected application is submitted after the deadline, the application will be considered late. NIAMS strongly encourages the PI of the parent research grant to contact both the scientific contact listed in this table and the NIAMS Program Officer of that grant. In support of this, the nominal payline for first competitive renewal applications for R01 awards to researchers who were ESIs when they competed for the initial NIDDK Type 1 R01 award is typically more generous than the regular payline for established investigators (see NIDDK Funding Policy). NIH and Grants.gov systems check the application against many of the application instructions upon submission. Does the application propose to use existing available resources, as applicable? Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html.